Valuation: Erasca, Inc.

Market Cap 6.32B 5.42B 5.06B 4.64B 8.73B 604B 8.88B 59.74B 23.39B 303B 23.73B 23.21B 1,002B P/E 2026 *
-18.4x
P/E 2027 * -28.8x
Enterprise Value 5.47B 4.69B 4.38B 4.02B 7.56B 523B 7.69B 51.72B 20.25B 262B 20.54B 20.1B 867B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
90.52%
Yield 2026 *
-
Yield 2027 * -
1 day-0.17%
1 week-2.74%
Current month-0.44%
1 month-5.74%
3 months+75.10%
6 months+45.84%
Current year+385.75%
1 week 17.3
Extreme 17.3
18.77
1 month 17.08
Extreme 17.08
19.96
Current year 3.36
Extreme 3.36
24.28
1 year 1.33
Extreme 1.3301
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.47
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2019
Director of Finance/CFO 43 06/01/2021
Chief Tech/Sci/R&D Officer - 24/05/2022
Director TitleAgeSince
Chairman 54 30/09/2018
Director/Board Member 79 31/05/2018
Director/Board Member 58 01/07/2018
Date Insider Type Main position Quantity % Market Cap.
10/08/26 Free

Chief Technology Officer

1,300,000 0.3745%
26/06/26 Free

Director

29,888 0.0096%
29/01/26 Free

General Counsel

560,000 0.1974%
Change 5-day change 1-year change 3-year change Capi.($)
-0.17%-2.74%+1,088.82%+619.92% 6.32B
+2.37%+2.30%+3.39%+22.74% 50.5B
-0.62%+4.58%+487.47%+624.71% 46.01B
+2.09%+4.96%+20.59%+95.21% 42.85B
+3.85%+3.13%+29.60%+16.50% 41.03B
-0.72%-3.91%+17.87%+47.98% 32.02B
+3.04%+1.89%+31.62%+143.62% 16.98B
+4.33%+1.63% - - 17.05B
+1.44%+1.52%+4.22%+31.00% 14.3B
+3.87%+1.98%+82.99%+45.80% 13.84B
Average +1.95%+1.53%+196.28%+183.05% 28.09B
Weighted average by Cap. +1.83%+2.26%+128.46%+165.31%

Financials

2026 *2027 *
Net sales - -
Net income -319M -273M -255M -234M -440M -30.46B -448M -3.01B -1.18B -15.28B -1.2B -1.17B -50.51B -218M -187M -175M -160M -302M -20.87B -307M -2.06B -808M -10.47B -820M -802M -34.6B
Net Debt -849M -728M -680M -624M -1.17B -81.11B -1.19B -8.02B -3.14B -40.68B -3.19B -3.12B -134B -762M -653M -610M -560M -1.05B -72.81B -1.07B -7.2B -2.82B -36.52B -2.86B -2.8B -121B
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
19/08/26 US$18.07 -0.17% 3,311,943
18/08/26 US$18.10 -0.98% 1,922,595
17/08/26 US$18.28 -0.54% 2,224,690
14/08/26 US$18.38 +2.91% 2,465,955
13/08/26 US$17.86 -3.88% 2,604,948
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
18.07USD
Average target price
23.50USD
Spread / Average Target
+30.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ERAS Stock